Table 2.
Composition of benzo(a)pyrene-DNA adducts (pmol/μg DNA) in colon and liver of ApcMin male mice treated with resveratrol (RVT) and benzo(a)pyrene (BaP; alone and in the presence of RVT).
| Organ/Adduct type | BaP | RVT prior to BaP | BaP + RVT |
|---|---|---|---|
| Colon | |||
| Deoxyadenosine adduct (dA) | 820 ± 80 | 710± 77 | 446± 40* |
| Deoxyguanosine adduct (dG) | 3640 ± 325 | 3525 ±335 | 2252 ± 212* |
| Deoxycytidine adduct (dC) | 240 ± 25 | 192±18 | 85 ± 8* |
| Deoxythymidine adduct (dT) | 100 ± 12 | 84 ± 9 | 28 ± 2* |
| Liver | |||
| Deoxyadenosine adduct (dA) | 358 ± 17 | 244 ± 12 | 154± 3.5* |
| Deoxyguanosine adduct (dG) | 1202 ± 34 | 1158 ± 24 | 882± 21* |
| Deoxycytidine adduct (dC) | 32 ± 1.2 | 21 ± 1.0 | 18 ± 0.8* |
| Deoxythymidine adduct (dT) | 9 ± 0.45 | 5 ± 0.35 | 4 ± 0.2* |
Values represent mean ± standard error (n = 10). Asterisks denote statistical significance (p < 0.05) of respective adduct types for BaP and RVT administered together compared to BaP alone administration.